Evidence map›Paper›PMID 25732572›Full record

Trial reportActa pharmacologica Sinica2015

Association of positively selected eIF3a polymorphisms with toxicity of platinum-based chemotherapy in NSCLC patients.

Ji-ye Yin, Xiang-guang Meng, Chen-yue Qian, Xiang-ping Li, Juan Chen, Yi Zheng, Rong Liu, Hong-hao Zhou, Zhao-qian Liu

Open access · bronzeAbstract readClinical Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Acta pharmacologica Sinica, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed, 2 pooled it
2.0field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 2 syntheses or guidelines pooled it, 28 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Article
  5. Review
  6. Review
  7. Article
  8. Article
  9. Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 1 country.

Ji-ye Yin1] Department of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha 410008, China; Institute of Clinical Pharmacology, Central South University [2] Hunan Key Laboratory of Pharmacogenetics, Changsha 410078, China [3] Hunan Province Cooperation Innovation Center for Molecular Target New Drug Study, Hengyang 421001, China.
Xiang-guang MengLaboratory of Cardiovascular Disease and Drug Research, Zhengzhou No 7 People's Hospital, Zhengzhou 450016, China.
Chen-yue Qian1] Department of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha 410008, China; Institute of Clinical Pharmacology, Central South University [2] Hunan Key Laboratory of Pharmacogenetics, Changsha 410078, China [3] Hunan Province Cooperation Innovation Center for Molecular Target New Drug Study, Hengyang 421001, China.
Xiang-ping LiDepartment of Pharmacy, Xiangya Hospital, Central South University, Changsha 410008, China.
Juan Chen1] Department of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha 410008, China; Institute of Clinical Pharmacology, Central South University [2] Hunan Key Laboratory of Pharmacogenetics, Changsha 410078, China [3] Hunan Province Cooperation Innovation Center for Molecular Target New Drug Study, Hengyang 421001, China.
Yi Zheng1] Department of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha 410008, China; Institute of Clinical Pharmacology, Central South University [2] Hunan Key Laboratory of Pharmacogenetics, Changsha 410078, China [3] Hunan Province Cooperation Innovation Center for Molecular Target New Drug Study, Hengyang 421001, China.
Rong Liu1] Department of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha 410008, China; Institute of Clinical Pharmacology, Central South University [2] Hunan Key Laboratory of Pharmacogenetics, Changsha 410078, China [3] Hunan Province Cooperation Innovation Center for Molecular Target New Drug Study, Hengyang 421001, China.
Hong-hao Zhou1] Department of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha 410008, China; Institute of Clinical Pharmacology, Central South University [2] Hunan Key Laboratory of Pharmacogenetics, Changsha 410078, China [3] Hunan Province Cooperation Innovation Center for Molecular Target New Drug Study, Hengyang 421001, China.
Zhao-qian Liu1] Department of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha 410008, China; Institute of Clinical Pharmacology, Central South University [2] Hunan Key Laboratory of Pharmacogenetics, Changsha 410078, China [3] Hunan Province Cooperation Innovation Center for Molecular Target New Drug Study, Hengyang 421001, China.
Central South University · CNXiangya Hospital Central South University · CNZhengzhou People's Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

aimEukaryotic translation initiation factor 3 subunit A (eIF3a) plays critical roles in regulating the initiation of protein translation, and eIF3a is highly expressed in lung cancer. In this study, we investigated the association of the positively selected SNPs of eIF3a with the response to and toxicity of platinum-based chemotherapy in Chinese patients with non-small cell lung cancer (NSCLC).

methodsSNP data for eIF3a locus were downloaded from HapMap database. For each SNP, haplotype, LD profile and population differentiation were analyzed. The long-range haplotype (LRH) test was employed to identify positively selected SNPs of eIF3a. A total of 325 NSCLC patients were enrolled and genotyped for these SNPs.

resultsFive positively selected (rs1409314, rs4752219, rs4752220, rs7091672 and rs10510050) and 5 non-positively selected SNPs (rs10886342, rs11198804, rs2275112, rs10787899 and rs4752269) were identified in the LRH test. However, none of them was correlated with the platinum-based chemotherapy response. In contrast, 4 of the positively selected SNPs (rs1409314, rs4752219, rs4752220 and rs7091672) were significantly correlated with the toxicities tested (neutropenia, anemia, thrombocytopenia, emesis and hepatotoxicity). In addition, rs10510050 was significantly correlated with thrombocytopenia, emesis and hepatotoxicity. None of the 5 non-positively selected SNPs was correlated with the 5 toxicities.

conclusionThe positively selected SNPs of eIF3a are significantly correlated with platinum-based chemotherapy toxicities in Chinese NSCLC patients.

Indexed as

Antineoplastic Combined Chemotherapy ProtocolsCarcinoma, Non-Small-Cell LungDrug-Related Side Effects and Adverse ReactionsEukaryotic Initiation Factor-3Lung NeoplasmsOrganoplatinum CompoundsPlatinum CompoundsPolymorphism, Single NucleotideAsian PeopleChinaChi-Square DistributionFemaleGene FrequencyGenetic Predisposition to DiseaseHaplotypesHumansEIF3A protein, humanEukaryotic Initiation Factor-3Organoplatinum CompoundsPlatinum Compounds

Identifiers

PMID25732572
PMCPMC4349930
OpenAlexW2074471784

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.